Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of MBS2320 in idiopathic pulmonary fibrosis
MOH_2023-09-28_012967Phase 2Not yet recruiting
- Sponsor
- Modern Biosciences
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing MBS2320 with Placebo (2 arms). Primary endpoint: Absolute change in forced vital capacity. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
Leramistat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on MOH_2023-09-28_012967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-28_012967.